Skip to main content

Fiscal Wizard · Single-issue tearsheet

ABT / Aug 31, 2026 Run #19055

ABT

Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Composite verdict

B 70.5 / 100
Bullish setup · Mean Reversion 15 drivers · 2 gates blocking
  • Stochastic RSI
  • Connors RSI(2)
  • Double 7s
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 3rd of 10 in Medical Devices

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 18 signals0% Bear
Momentum Bullish 87Mean-reversion Bullish 63

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -68%
Asset value $30.13Earnings power value $37.30Price $110.44

Priced above its no-growth earnings power value ($37.30/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

41.1 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion 78
Margin of Safety 0
EBITDA Margin 76
EPS Growth (YoY) 0
Total Shareholder Yield 72
Inventory Turnover 0

Technicals Bullish

100.0 / 100

Bullish setup leads (Stochastic RSI, Connors RSI(2), Double 7s); bears gated by guards. · 44 signals shown.

Strongest
Weakest
Stochastic RSI 93
Connors RSI(2) 86
Double 7s 84

Risk Gates

2 blocking 3 caution

2 guards active, 22 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Piotroski F-Score Caution

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Weak-trend caution

Weak trend strength blocks trend-following signals in either direction.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ABT.